Nicotinamide riboside, cognitive scores and brain blood flow: two questions in one ageing study
An NAD-related ageing study selected cognitive scores as its primary measure and cerebrovascular reactivity as another outcome.

An NAD-related ageing study selected cognitive scores as its primary measure and cerebrovascular reactivity as another outcome. The tested material was a nicotinamide riboside preparation. A change in blood-flow response can be biologically informative while remaining distinct from the performance recorded on a cognitive test.
A vascular response and a cognitive score may differ
Suppose a vascular measure changes and scores stay similar. That pattern would raise a research question about the path from physiology to function; it would not be internally contradictory. The opposite pattern would also need interpretation. Look for the actual group comparison and uncertainty for each result separately. The presence of NAD in the study title does not make a finished NAD+ pen the tested intervention, and short follow-up does not establish prevention of later dementia.
Find out how a score is constructed
A memory score can change while an imaging measurement of blood flow stays similar, or vice versa. Write down the assessment instrument next to the score and the imaging unit next to the flow value. A relationship between them requires comparing both observations in the participating people, not simply putting two group averages side by side.
Cognitive test performance depends on the instrument being used, while cerebrovascular reactivity reflects a response of blood vessels under the test conditions. An explanation linking the two would ideally show how the measures relate within participants and whether the association is reproducible. Similar-looking group averages alone cannot demonstrate the proposed causal pathway.
Participant and measurement details
- People in the record: 64 (actual enrollment). Eligible ages: 60 years to 90 years.
- Clinical setting: Mild Cognitive Impairment.
- Named study interventions: Niagen®, Placebo.
- Study design: phase 1, phase 2, interventional, randomized, parallel. Masking: double.
- Measured here: Cognitive scores at baseline and week twelve in older adults with mild cognitive impairment.
- Research locations listed in the record include: Newark, United States.
- Study calendar in the registration: start 2019-03-20; primary completion 2024-01-08.
- Primary record: University of Delaware. ClinicalTrials.gov, NCT03482167.
In Bali, distinguish a finished NAD+ pen from an oral nicotinamide riboside preparation before even comparing outcomes. Next separate cognitive scores from vascular reactivity. Those two checks eliminate both the molecule substitution and the endpoint substitution that can occur in a short sales description.
